Balchem (BCPC) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	BALCHEM CORP
Entity Central Index Key	9326
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		31,089,601
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$56,613	$50,287
Accounts receivable, net of allowance for doubtful accounts of $265 and $288 at March 31, 2015 and December 31, 2014	64,088	71,982
Inventories	50,451	49,623
Prepaid expenses	3,370	4,545
Deferred income taxes	1,372	1,390
Other current assets	3,233	3,475
Total current assets	179,127	181,302
Property, plant and equipment, net	133,494	131,588
Goodwill	383,906	383,906
Intangible assets with finite lives, net	154,135	160,394
Other assets	4,180	4,341
Total assets	854,842	861,531
Current liabilities:
Trade accounts payable	20,041	24,352
Accrued expenses	16,555	15,614
Accrued compensation and other benefits	4,735	9,137
Dividends payable	0	9,251
Income taxes payable	1,789	2,168
Current portion of long-term debt	35,000	35,000
Total current liabilities	78,120	95,522
Long-term debt	288,750	297,500
Deferred income taxes	70,701	70,661
Other long-term obligations	6,047	5,950
Total liabilities	443,618	469,633
Commitments and contingencies (note 14)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $.0667 par value. Authorized 60,000,000 shares; 31,056,901 shares issued and outstanding at March 31, 2015 and 30,845,586 shares issued and outstanding at December 31, 2014	2,071	2,058
Additional paid-in capital	104,113	97,289
Retained earnings	310,374	295,202
Accumulated other comprehensive loss	-5,334	-2,651
Total stockholders' equity	411,224	391,898
Total liabilities and stockholders' equity	$854,842	$861,531

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Current assets:
Allowance for doubtful accounts	$265	$288
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$25	$25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.07	$0.07
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	31,056,901	30,845,586
Common stock, shares outstanding (in shares)	31,056,901	30,845,586

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Earnings (unaudited) [Abstract]
Net sales	$144,862	$85,995
Cost of sales	101,732	62,780
Gross margin	43,130	23,215
Operating expenses:
Selling expenses	11,786	4,189
Research and development expenses	1,448	773
General and administrative expenses	4,858	4,898
Operating expenses	18,092	9,860
Earnings from operations	25,038	13,355
Other expenses (income):
Interest income	-2	-46
Interest expense	1,881	1
Other, net	74	28
Earnings before income tax expense	23,085	13,372
Income tax expense	7,913	4,478
Net earnings	$15,172	$8,894
Net earnings per common share - basic (in dollars per share)	$0.49	$0.30
Net earnings per common share - diluted (in dollars per share)	$0.48	$0.29

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Comprehensive Income (unaudited) [Abstract]
Net earnings	$15,172	$8,894
Other comprehensive loss, net of tax:
Net foreign currency translation adjustment	-2,680	-18
Net change in postretirement benefit plan, net of taxes of $2 and $1 for the three months ended March 31, 2015 and 2014	-3	-2
Other comprehensive loss	-2,683	-20
Comprehensive income	$12,489	$8,874

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Other comprehensive loss, net of tax:
Net change in postretirement benefit plan, taxes	$2	$1

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net earnings	$15,172	$8,894
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	10,026	2,631
Stock compensation expense	1,174	988
Deferred income taxes	4	55
Provision for doubtful accounts	-16	0
Foreign currency transaction loss	34	36
Loss on disposal of assets	85	0
Changes in assets and liabilities
Accounts receivable	7,125	-4,387
Inventories	-1,286	-50
Prepaid expenses and other current assets	1,322	526
Accounts payable and accrued expenses	-7,010	400
Income taxes	-168	1,123
Customer deposits and other deferred revenue	11	0
Other	125	24
Net cash provided by operating activities	26,598	10,240
Cash flows from investing activities:
Deposit held in escrow	0	-5,500
Capital expenditures	-6,368	-1,138
Intangible assets acquired	-387	-27
Net cash used in investing activities	-6,755	-6,665
Cash flows from financing activities:
Principal payments on long-term debt	-8,750	0
Repayments of short-term obligations	0	-89
Proceeds from stock options exercised	3,175	1,327
Excess tax benefits from stock compensation	2,488	1,689
Dividends paid	-9,251	-7,856
Purchase of treasury stock	0	-33
Net cash provided by financing activities	-12,338	-4,962
Effect of exchange rate changes on cash	-1,179	-30
Increase (decrease) in cash and cash equivalents	6,326	-1,417
Cash and cash equivalents beginning of period	50,287	208,747
Cash and cash equivalents end of period	$56,613	$207,330

CONDENSED_CONSOLIDATED_FINANCI

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2015
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS [Abstract]
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 1 – CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	The condensed consolidated financial statements presented herein have been prepared by the Company in accordance with the accounting policies described in its December 31, 2014 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2014. References in this report to the “Company” mean either Balchem Corporation or Balchem Corporation and its subsidiaries, including  BCP Ingredients, Inc., Aberco, Inc., Balchem BV, Balchem Italia Srl, Performance Chemicals & Ingredients Company, SensoryEffects Powder Systems, Inc., SensoryEffects Cereal Systems, Inc., SensoryEffects Flavor Company, SensoryEffects International Sales, Inc., and SEPS Reading LLC, on a consolidated basis, as the context requires.
	In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 and therefore do not include some information and notes necessary to conform to annual reporting requirements. Certain prior year amounts have been reclassified to conform to current year presentation. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results expected for the full year or any interim period.
	Retrospective Revision of Certain Prior Period Information
	During the first quarter of fiscal year 2015, information that our chief operating decision maker regularly reviews for purposes of allocating resources and assessing performance changed, and as a result, the Company changed its communication to external investors. Therefore, beginning in fiscal year 2015, we are reporting our financial performance based on our new segments described in Note 10 – Segment Information. We have retrospectively revised certain prior period amounts to conform to the way we internally manage and monitor segment performance during the current fiscal year. This change impacted Note 6 – Intangible Assets and Note 10 – Segment Information, with no impact on consolidated net income or cash flows.
	During the first quarter of fiscal year 2015, the Company completed its review of the acquired tax balances associated with the SensoryEffects acquisition.  As a result, the following December 31, 2014 balances were retrospectively revised as follows: goodwill and deferred income taxes were increased by $260. The revision is measured as of the acquisition date and considers adjustments that would have been recognized had the deferred taxes been recorded as of the acquisition date. There was no impact on consolidated net income or cash flows. See Note 2.

ACQUISITION_OF_PERFORMANCE_CHE

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY	3 Months Ended
	Mar. 31, 2015
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY [Abstract]
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY	NOTE 2—ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY
	On May 7, 2014, the Company acquired 100 percent (the “Acquisition”) of the outstanding common shares of Performance Chemicals & Ingredients Company (d/b/a SensoryEffects), a privately held supplier of customized food and ingredient systems, headquartered in St. Louis, Missouri. The Company made payments of approximately $569 million on the acquisition date, amounting to approximately $494 million to the former shareholders, including adjustments for working capital acquired, and approximately $75 million to SensoryEffects’ lenders to pay off all SensoryEffects bank debt. SensoryEffects is a leader in powder, solid and liquid flavor systems, creamer and specialty emulsified powders, cereal-based products and other functional ingredient food and beverage delivery systems. The Acquisition of SensoryEffects accelerates the Company’s growth into the health and wellness markets. SensoryEffects was merged with the Company’s Food, Pharma & Nutrition segment, strengthening its market leadership position, and the segment was renamed SensoryEffects.
	The goodwill of $355,391 arising from the Acquisition consists largely of expected synergies, including the combined entities experience and technical problem solving capabilities, and acquired workforce. The goodwill is assigned to the SensoryEffects segment and approximately $20,466 is expected to be tax deductible for income tax purposes.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed.
	Cash and cash equivalents	$	2,635
	Accounts receivable		25,674
	Inventories		32,000
	Property, plant and equipment		75,850
	Customer relationships		130,300
	Trade names		31,100
	Developed technology		3,200
	Other assets		3,955
	Indemnification asset		1,650
	Trade accounts payable		(10,427	)
	Accrued expenses		(6,326	)
	Bank debt		(75,550	)
	Deferred income taxes		(75,760	)
	Goodwill		355,391
	Amount paid to shareholders		493,692
	SensoryEffects bank debt paid on purchase date		75,550
	Total amount paid on acquisition date	$	569,242
	As a result of our reviews of the tax balances, a retrospective revision of an additional $260 to deferred income taxes and goodwill was made to the purchase price allocation as of May 7, 2014.
	Customer relationships are amortized over a 10-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade names and developed technology are amortized over 10 years and 5 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
	The Company is indemnified for tax liabilities prior to the Acquisition date. The indemnification asset balance increased by $54 from January 1, 2015 to March 31, 2015 to $1,976.
	The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2013.
		Three Months Ended					Three Months Ended
		31-Mar-15					31-Mar-14
		Net Sales			Net Earnings		Net Sales		Net Earnings
	SensoryEffects actual results included in the Company’s consolidated income statement from January 1, 2015 through March 31, 2015	$	54,540		$	2,906	$	-0-	$	-0-
	Supplemental pro forma combined financial information	$	144,862		$	15,172	$	144,607	$	11,852
	Basic earnings per share				$	0.49			$	0.39
	Diluted earnings per share				$	0.48			$	0.38
	2014 supplemental pro forma earnings for the three months ended March 31, 2014, exclude $1,268 of acquisition-related costs incurred. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if the SensoryEffects acquisition had occurred at the beginning of the periods presented and is not intended to be a projection of future results.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 3 – STOCKHOLDERS’ EQUITY
	STOCK-BASED COMPENSATION
	The Company records stock-based compensation in accordance with the provisions of ASC 718, “Compensation-Stock Compensation.” The Company’s results for the three months ended March 31, 2015 and 2014 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:
			Increase/(Decrease) for the
			Three Months Ended March 31,
			2015				2014
	Cost of sales		$	212			$	148
	Operating expenses			962				840
	Net earnings			(760	)			(653	)
	As required by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.
	The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of March 31, 2015, the plans had 3,825,592 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, four years for employee restricted stock awards, three years for employee performance share awards, and four to seven years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.
	Option activity for the three months ended March 31, 2015 and 2014 is summarized below:
	For the three months ended March 31, 2015		Shares (000s)				Weighted Average			Aggregate Intrinsic		Weighted Average Remaining Contractual
							Exercise			Value		Term
							Price			($000s)
	Outstanding as of December 31, 2014			1,470			$	27.35		$	57,742
	Granted			197				58.52
	Exercised			(192	)			16.52
	Forfeited			(1	)			45.08
	Outstanding as of March 31, 2015			1,474			$	32.93		$	33,736	6.2
	Exercisable as of March 31, 2015			1,040			$	24.75		$	31,849	4.9
	For the three months ended March 31, 2014		Shares (000s)				Weighted Average			Aggregate Intrinsic		Weighted Average Remaining Contractual
							Exercise			Value		Term
							Price			($000s)
	Outstanding as of December 31, 2013			1,893			$	20.94		$	71,465
	Granted			158				50.57
	Exercised			(125	)			10.6
	Forfeited			(13	)			43.1
	Outstanding as of March 31, 2014			1,913			$	23.92		$	53,946		5.6
	Exercisable as of March 31, 2014			1,504			$	19.28		$	49,392		4.7
	ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.6% and 0.6%; expected volatilities of 33% and 33%; risk-free interest rates of 1.8% and 1.7%; and expected lives of 5.5 and 5.6 years, in each case for the three months ended March 31, 2015 and 2014, respectively.
	The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
	Other information pertaining to option activity during the three months ended March 31, 2015 and 2014 was as follows:
		Three Months Ended
		March 31,
		2015				2014
	Weighted-average fair value of options granted		$	18.42			$	15.98
	Total intrinsic value of stock options exercised ($000s)		$	8,039			$	5,418
	Non-vested restricted stock activity for the three months ended March 31, 2015 and 2014 is summarized below:
	Three months ended March 31, 2015		Shares (000s)				Weighted
							Average Grant
							Date Fair
							Value
	Non-vested balance as of December 31, 2014			134			$	38.13
	Granted			19				58.52
	Vested			(10	)			14.37
	Forfeited			-				-
	Non-vested balance as of March 31, 2015			143			$	42.53
	Three months ended March 31, 2014		Shares (000s)				Weighted Average Grant Date Fair
							Value
	Non-vested balance as of December 31, 2013			172			$	33.69
	Granted			20				50.49
	Vested			(2	)			35.79
	Forfeited			(2	)			32.7
	Non-vested balance as of March 31, 2014			188			$	35.42
	During the three months ended March 31, 2015, the Company granted 24,010 equity-settled performance shares (PS’s) with a weighted average fair value of $58.78 to certain employees. There were no vested or forfeited PS during the three months ended March 31, 2015. PS awards provide the recipient the right to receive a certain number of shares of the Company’s common stock in the future, subject to an (1) EBITDA performance  hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents established at January 1, 2015. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests.  The assumptions used in the fair value determination were: risk free interest rate: 1.00%; dividend yield: 0.5%; volatility: 34% and initial TSR -6.9%. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved.  The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.
	As of March 31, 2015 and 2014, there was $10,622 and $8,259, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of March 31, 2015, the unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.8 years. The Company estimates that share-based compensation expense for the year ended December 31, 2015 will be approximately $4,700.
	REPURCHASE OF COMMON STOCK
	The Company has an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,105,231 shares have been purchased, none of which remained in treasury at March 31, 2015. During the three months ended March 31, 2015, no shares were purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
INVENTORIES [Abstract]
INVENTORIES	NOTE 4 – INVENTORIES
	Inventories at March 31, 2015 and December 31, 2014 consisted of the following:
		March 31,		December 31,
		2015		2014
	Raw materials	$	17,745	$	19,822
	Work in progress		2,439		1,989
	Finished goods		30,267		27,812
	Total inventories	$	50,451	$	49,623

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2015
PROPERTY, PLANT AND EQUIPMENT [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at March 31, 2015 and December 31, 2014 are summarized as follows:
		March 31,		December 31,
		2015		2014
	Land	$	2,997	$	3,130
	Building		30,723		31,030
	Equipment		149,036		150,170
	Construction in progress		14,218		10,969
			196,974		195,299
	Less: accumulated depreciation		63,480		63,711
	Property, plant and equipment, net	$	133,494	$	131,588

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
INTANGIBLE ASSETS [Abstract]
INTANGIBLE ASSETS	NOTE 6 – INTANGIBLE ASSETS
	The Company had goodwill in the amount of $383,906 as of March 31, 2015 and December 31, 2014 subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
	As discussed in Note 10 – Segment Information, during the first quarter of fiscal year 2015, information that our chief operating decision maker regularly reviews for purposes of allocating resources and assessing performance changed, and as a result, the Company changed its communication to external investors. We allocated goodwill to our new reporting units using a relative fair value approach.
		March 31,		December 31,
		2015		2014
	Specialty Products	$	7,160	$	7,160
	SensoryEffects		363,784		363,784
	Animal Nutrition and Health		11,734		11,734
	Industrial Products		1,228		1,228
	Total	$	383,906	$	383,906
	Identifiable intangible assets with finite lives at March 31, 2015 and December 31, 2014 are summarized as follows:
		Amortization		Gross		Accumulated		Gross		Accumulated
		Period		Carrying		Amortization		Carrying		Amortization
		(in years)		Amount at 3/31/15		at 3/31/15		Amount at		at 12/31/14
								12/31/14
	Customer relationships & lists		10	$	167,442	$	46,822	$	167,442	$	41,238
	Trademarks & trade names		17		32,014		3,332		32,014		2,540
	Developed technology		5		3,200		577		3,200		420
	Regulatory registration costs		10-May		2,012		705		1,704		667
	Patents & trade secrets		15-17		1,705		955		1,665		933
	Other		10-May		754		601		754		587
				$	207,127	$	52,992	$	206,779	$	46,385
	Amortization of identifiable intangible assets was approximately $6,600 for the three months ended March 31, 2015. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense for the remainder of 2015 is $19,900, approximately $24,350 for 2016, $20,350 for 2017, $18,100 for 2018, $16,250 for 2019 and $14,500 for 2020. At March 31, 2015, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the three months ended March 31, 2015.

LONGTERM_DEBT

LONG-TERM DEBT	3 Months Ended
	Mar. 31, 2015
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	NOTE 7 – LONG-TERM DEBT
	On May 7, 2014, the Company and a bank syndicate entered into a loan agreement providing for a senior secured term loan of $350,000 and revolving loan of $100,000 (collectively referred to as the “loans”). The term loan and $50,000 of the revolving loan were used to fund the Performance Chemicals & Ingredients Company acquisition (see Note 2) and for general corporate purposes. At March 31, 2015, the Company had a total of $323,750 of debt outstanding. The term loan is payable in quarterly installments of $8,750 commencing on September 30, 2014, with the outstanding principal due on the maturity date. The Company may draw on the revolving loan at its discretion and the revolving loan does not have installments and all outstanding amounts are due on the maturity date. The loans may be voluntarily prepaid in whole or in part without premium or penalty and have a maturity date of May 7, 2019. The loans are subject to an interest rate equal to LIBOR or a fluctuating rate as defined by the loan agreement, at the Company’s discretion; plus an applicable rate. The applicable rate is based upon the Company’s consolidated leverage ratio, as defined in the loan agreement, and the interest rate was 1.67% at March 31, 2015. The Company has $100,000 of undrawn revolving loan at March 31, 2015 that is subject to a commitment fee; which is based on the Company’s consolidated leverage ratio as defined in the loan agreement. The loan agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated fixed charge coverage ratio to exceed a certain minimum ratio. At March 31, 2015, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements are secured by assets of the company.
	The following table summarizes the future minimum debt payments:
		2015		2016		2017		2018		2019
	Current portion of long-term debt	$	26,250	$	8,750		-		-		-
	Long-term debt		-		26,250	$	35,000	$	35,000	$	192,500
	Total	$	26,250	$	35,000	$	35,000	$	35,000	$	192,500
	Costs associated with the issuance of debt instruments are capitalized and amortized over the terms of the respective financing arrangements using the effective interest method. If debt is retired early, the related unamortized costs are expensed in the period the debt is retired. Capitalized costs net of accumulated amortization total $1,982 at March 31, 2015. Amortization expense pertaining to these costs totaled $157 for the three months ended March 31, 2015, and is included in interest expense in the accompanying condensed consolidated statement of earnings.

NET_EARNINGS_PER_SHARE

NET EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2015
NET EARNINGS PER SHARE [Abstract]
NET EARNINGS PER SHARE	NOTE 8 – NET EARNINGS PER SHARE
	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:
	Three months ended March 31, 2015	Net		Number of		Per Share
		Earnings		Shares		Amount
		(Numerator)		(Denominator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	15,172		30,842,208	$	0.49
	Effect of dilutive securities – stock options and restricted stock				616,096
	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	15,172		31,458,304	$	0.48
	Three months ended March 31, 2014	Net		Number of		Per Share
		Earnings		Shares		Amount
		(Numerator)		(Denominator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	8,894		30,146,705	$	0.3
	Effect of dilutive securities – stock options and restricted stock				932,299
	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	8,894		31,079,004	$	0.29
	The Company had stock options covering 399,868 and 11,500 shares at March 31, 2015 and 2014, respectively, that could potentially dilute basic earnings per share in future periods that were not included in diluted earnings per share because their effect on the period presented was anti-dilutive.
	The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and performance shares and they participate on a one-for-one basis with holders of common stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 9 – INCOME TAXES
	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, “Accounting for Uncertainty in Income Taxes.”  ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. All of the unrecognized tax benefits, if recognized in future periods, would impact the Company’s effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of March 31, 2015, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2010. During the three months ended March 31, 2015, the increase in the amount of unrecognized tax benefits was primarily related to the aforementioned Acquisition (See Note 2) of Performance Chemicals & Ingredients Company (d/b/a SensoryEffects). The Acquisition resulted in an assumed liability for unrecognized tax benefits based on an estimated fair value of $1,976. The Company is indemnified for this liability, and as such, has recognized a corresponding indemnification asset of $1,976. During the three months ended March 31, 2014, there was no significant change to the amount of unrecognized tax benefits. As of March 31, 2015 and December 31, 2014, the Company had approximately $5,400 and $5,200, respectively, of unrecognized tax benefits, which are included in other long-term obligations on the Company’s consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at March 31, 2015 and December 31, 2014 was approximately $1,810 and $1,643, respectively, and is included in other long-term obligations.

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION [Abstract]
SEGMENT INFORMATION	NOTE 10 – SEGMENT INFORMATION
	During the first quarter of fiscal year 2015, information that our chief operating decision maker regularly reviews for purposes of allocating resources and assessing performance changed, and as a result, the Company changed its communication to external investors. Therefore, beginning in fiscal year 2015, we are reporting our financial performance based on our new segments; Specialty Products, SensoryEffects, Animal Nutrition & Health, and Industrial Products. We have retrospectively revised certain prior period amounts to conform to the way we internally manage and monitor segment performance during the current fiscal year. Our reportable segments are described below.
	SensoryEffects
	Our SensoryEffects segment supplies ingredients in the food and beverage industry; providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems.  Our products include creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice & dairy bases, chocolate systems, ice cream bases & variegates, ready-to-eat cereals, grain based snacks, and cereal based ingredients. Additionally, we provide microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. We also produce and market human grade choline nutrient products through this segment for wellness applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function.
	Animal Nutrition & Health
	Our Animal Nutrition & Health (“ANH”) segment provides nutritional products derived from our microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, our microencapsulated products boosts health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. Our proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. Choline deficiency can result in reduced growth and perosis in poultry; fatty liver, kidney necrosis and general poor health condition in swine.
	Sales of specialty products for the animal nutrition and health industry are highly dependent on dairy industry economics as well as the ability of the Company to leverage the results of university and field research on the animal health benefits of the Company’s products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to increase production efficiencies in order to maintain its low-cost position to effectively compete in a competitive global marketplace.
	Industrial Products
	Certain derivatives of choline chloride are manufactured and sold into industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells. Our products offer an attractive, effective and more environmentally responsible alternative than other clay stabilizers. Industrial grade Choline Bicarbonate is completely chloride free and our Choline Chloride reduces the amount of chlorides released into the environment up to 75% when compared to potassium chloride. The Industrial Products segment also includes the manufacture and sale of methylamines. Methylamines are a primary building block for the manufacture of choline products and are produced at our Italian operation and sold for a wide range of industrial applications in Europe.
	Specialty Products
	Our Specialty Products segment operates commercially as ARC Specialty Products.
	Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Our 100% ethylene oxide product is distributed in uniquely designed, recyclable, double-walled, stainless steel drums to assure compliance with safety, quality and environmental standards as outlined by the EPA and the DOT. Our inventory of these specially built drums, along with our two filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. We also sell single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.
	Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. We distribute our propylene oxide product primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the EPA and the DOT. Our inventory of these cylinders also represents a significant capital investment. Propylene oxide is also sold to customers seeking smaller (as opposed to bulk) quantities and whose requirements include utilization in various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings
	Business Segment Assets:
		March 31,			December 31,
		2015			2014
	Specialty Products	$	25,752		$	24,913
	SensoryEffects		652,470			656,130
	Animal Nutrition & Health		92,804			90,650
	Industrial Products		21,597			32,330
	Other Unallocated		62,219			57,508
	Total	$	854,842		$	861,531
	Depreciation/Amortization:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	341		$	360
	SensoryEffects		7,639			299
	Animal Nutrition & Health		1,546			1,521
	Industrial Products		343			451
	Total	$	9,869		$	2,631
	Capital Expenditures:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	211		$	17
	SensoryEffects		2,626			298
	Animal Nutrition & Health		3,260			704
	Industrial Products		271			119
	Total	$	6,368		$	1,138
	Business Segment Net Sales:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	13,579		$	12,792
	SensoryEffects		67,757			12,150
	Animal Nutrition & Health		42,706			40,853
	Industrial Products		20,820			20,200
	Total	$	144,862		$	85,995
	Business Segment Earnings Before Income Taxes:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	5,701		$	4,806
	SensoryEffects		7,706			2,601
	Animal Nutrition & Health		8,510			4,159
	Industrial Products		3,121			3,134
	Transaction and integration costs		-			(1,345	)
	Interest and other income (expense)		(1,953	)		17
	Total	$	23,085		$	13,372
	Transaction and integration costs are primarily related to the definitive agreement to acquire Performance Chemicals & Ingredients Company (d/b/a SensoryEffects; see Note 2).
	The following table summarizes domestic (U.S.) and foreign sales for the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
	2015			2014
Domestic	$	121,776		$	56,144
Foreign		23,086			29,851
Total	$	144,862		$	85,995

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2015
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 11 – SUPPLEMENTAL CASH FLOW INFORMATION
	Cash paid during the three months ended March 31, 2015 and 2014 for income taxes and interest is as follows:
		Three months Ended
		March 31,
			2015		2014
	Income taxes		$	5,527	$	1,640
	Interest		$	1,723	$	-

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	3 Months Ended
	Mar. 31, 2015
ACCUMULATED OTHER COMPREHENSIVE LOSS [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	NOTE 12 – ACCUMULATED OTHER COMPREHENSIVE LOSS
	The changes in accumulated other comprehensive loss were as follows:
		Three Months Ended
		March 31,
		2015			2014
	Net foreign currency translation adjustment	$	(2,680	)	$	(18	)
	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		-			2
	Total before tax		(5	)		(3	)
	Tax		2			1
	Net of tax		(3	)		(2	)
	Total other comprehensive loss	$	(2,683	)	$	(20	)
	Accumulated other comprehensive loss at March 31, 2015 consisted of the following:
		Foreign currency			Postretirement			Total
		translation			benefit plan
		adjustment
	Balance December 31, 2014	$	(2,702	)	$	51		$	(2,651	)
	Other comprehensive loss		(2,680	)		(3	)		(2,683	)
	Balance March 31, 2015	$	(5,382	)	$	48		$	(5,334	)

EMPLOYEE_BENEFIT_PLAN

EMPLOYEE BENEFIT PLAN	3 Months Ended
	Mar. 31, 2015
EMPLOYEE BENEFIT PLAN [Abstract]
EMPLOYEE BENEFIT PLAN	NOTE 13 – EMPLOYEE BENEFIT PLAN
	The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility.
	Net periodic benefit costs for such retirement medical plan were as follows:
		Three months Ended
		March 31,
		2015			2014
	Service cost	$	13		$	14
	Interest cost		9			12
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		-			2
	Net periodic benefit cost	$	17		$	23
	The amount recorded for this obligation on the Company’s balance sheet as of March 31, 2015 and December 31, 2014 is $1,134 and $1,111, respectively, and is included in other long-term obligations. The plan is unfunded and approved claims are paid from Company funds. Historical cash payments made under such plan have typically been less than $100 per year.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES
	In 2015, the Company entered into a six (6) year, nine (9) month lease in St. Louis, Missouri for approximately 9,100 square feet of office space. The office space serves as SensoryEffects’ selling and general offices.
	In 2012, the Company entered into a six (6) year lease extension for approximately 20,000 square feet of office space in New Hampton, New York. The office space serves as the Company’s general offices and as a laboratory facility. In 2013, SensoryEffects entered into a three (3) year lease for approximately 40,000 square feet of warehouse space in St. Louis, Missouri. The Company leases most of its vehicles and office equipment under non-cancelable operating leases, which primarily expire at various times through 2029.
	Rent expense charged to operations under such lease agreements for the three months ended March 31, 2015 and 2014 aggregated approximately $547 and $269, respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at March 31, 2015 are as follows:
	Year
	April 1, 2015 to December 31, 2015	$	1,589
	2016		1,818
	2017		1,580
	2018		1,309
	2019		789
	2020		499
	Thereafter		1,937
	Total minimum lease payments	$	9,521
	In 1982, the Company discovered and thereafter removed a number of buried drums containing unidentified waste material from the Company’s site in Slate Hill, New York. The Company thereafter entered into a Consent Decree to evaluate the drum site with the New York Department of Environmental Conservation (“NYDEC”) and performed a Remedial Investigation/Feasibility Study that was approved by NYDEC in February 1994. Based on NYDEC requirements, the Company cleaned the area and removed soil from the drum burial site, which was completed in 1996. The Company continues to be involved in discussions with NYDEC to evaluate test results and determine what, if any, additional actions will be required on the part of the Company to close out the remediation of this site. Additional actions, if any, would likely require the Company to continue monitoring the site. The cost of such monitoring has been less than $5 per year for the period 2004 to date.
	The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources (“MDNR”) included removal of dioxin contaminated soil and equipment, capping of areas of residual contamination in four relatively small areas of the site separate from the manufacturing facilities, and the installation of wells to monitor groundwater and surface water contamination by organic chemicals. No ground water or surface water treatment was required. The Company believes that remediation of the site is complete. In 1998, the EPA certified the work on the contaminated soils to be complete. In February 2000, after the conclusion of two years of monitoring groundwater and surface water, the former owner submitted a draft third party risk assessment report to the EPA and MDNR recommending no further action. The prior owner is awaiting the response of the EPA and MDNR to the draft risk assessment.
	While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that is implementing the above-described Superfund remedy.
	From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2015
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 15 – FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at March 31, 2015 and December 31, 2014 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, are carried at cost which approximates fair value due to the short-term maturity of these instruments. Cash and cash equivalents at March 31, 2015 include $772 in money market funds. The money market funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

ACQUISITION_OF_PERFORMANCE_CHE1

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY (Tables)	3 Months Ended
	Mar. 31, 2015
ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY [Abstract]
Estimated fair values of the assets acquired and liabilities assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed.
	Cash and cash equivalents	$	2,635
	Accounts receivable		25,674
	Inventories		32,000
	Property, plant and equipment		75,850
	Customer relationships		130,300
	Trade names		31,100
	Developed technology		3,200
	Other assets		3,955
	Indemnification asset		1,650
	Trade accounts payable		(10,427	)
	Accrued expenses		(6,326	)
	Bank debt		(75,550	)
	Deferred income taxes		(75,760	)
	Goodwill		355,391
	Amount paid to shareholders		493,692
	SensoryEffects bank debt paid on purchase date		75,550
	Total amount paid on acquisition date	$	569,242
Acquisition of unaudited pro forma information	The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2013.
		Three Months Ended					Three Months Ended
		31-Mar-15					31-Mar-14
		Net Sales			Net Earnings		Net Sales		Net Earnings
	SensoryEffects actual results included in the Company’s consolidated income statement from January 1, 2015 through March 31, 2015	$	54,540		$	2,906	$	-0-	$	-0-
	Supplemental pro forma combined financial information	$	144,862		$	15,172	$	144,607	$	11,852
	Basic earnings per share				$	0.49			$	0.39
	Diluted earnings per share				$	0.48			$	0.38

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]
Effect of compensation cost on earnings	The Company’s results for the three months ended March 31, 2015 and 2014 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:
			Increase/(Decrease) for the
			Three Months Ended March 31,
			2015				2014
	Cost of sales		$	212			$	148
	Operating expenses			962				840
	Net earnings			(760	)			(653	)
Summary of stock option activity	Option activity for the three months ended March 31, 2015 and 2014 is summarized below:
	For the three months ended March 31, 2015		Shares (000s)				Weighted Average			Aggregate Intrinsic		Weighted Average Remaining Contractual
							Exercise			Value		Term
							Price			($000s)
	Outstanding as of December 31, 2014			1,470			$	27.35		$	57,742
	Granted			197				58.52
	Exercised			(192	)			16.52
	Forfeited			(1	)			45.08
	Outstanding as of March 31, 2015			1,474			$	32.93		$	33,736	6.2
	Exercisable as of March 31, 2015			1,040			$	24.75		$	31,849	4.9
	For the three months ended March 31, 2014		Shares (000s)				Weighted Average			Aggregate Intrinsic		Weighted Average Remaining Contractual
							Exercise			Value		Term
							Price			($000s)
	Outstanding as of December 31, 2013			1,893			$	20.94		$	71,465
	Granted			158				50.57
	Exercised			(125	)			10.6
	Forfeited			(13	)			43.1
	Outstanding as of March 31, 2014			1,913			$	23.92		$	53,946		5.6
	Exercisable as of March 31, 2014			1,504			$	19.28		$	49,392		4.7
Other information pertaining to stock option activity	Other information pertaining to option activity during the three months ended March 31, 2015 and 2014 was as follows:
		Three Months Ended
		March 31,
		2015				2014
	Weighted-average fair value of options granted		$	18.42			$	15.98
	Total intrinsic value of stock options exercised ($000s)		$	8,039			$	5,418
Non-vested restricted stock activity	Non-vested restricted stock activity for the three months ended March 31, 2015 and 2014 is summarized below:
	Three months ended March 31, 2015		Shares (000s)				Weighted
							Average Grant
							Date Fair
							Value
	Non-vested balance as of December 31, 2014			134			$	38.13
	Granted			19				58.52
	Vested			(10	)			14.37
	Forfeited			-				-
	Non-vested balance as of March 31, 2015			143			$	42.53
	Three months ended March 31, 2014		Shares (000s)				Weighted Average Grant Date Fair
							Value
	Non-vested balance as of December 31, 2013			172			$	33.69
	Granted			20				50.49
	Vested			(2	)			35.79
	Forfeited			(2	)			32.7
	Non-vested balance as of March 31, 2014			188			$	35.42

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
INVENTORIES [Abstract]
Inventories	Inventories at March 31, 2015 and December 31, 2014 consisted of the following:
		March 31,		December 31,
		2015		2014
	Raw materials	$	17,745	$	19,822
	Work in progress		2,439		1,989
	Finished goods		30,267		27,812
	Total inventories	$	50,451	$	49,623

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2015
PROPERTY, PLANT AND EQUIPMENT [Abstract]
Property, plant and equipment	Property, plant and equipment at March 31, 2015 and December 31, 2014 are summarized as follows:
		March 31,		December 31,
		2015		2014
	Land	$	2,997	$	3,130
	Building		30,723		31,030
	Equipment		149,036		150,170
	Construction in progress		14,218		10,969
			196,974		195,299
	Less: accumulated depreciation		63,480		63,711
	Property, plant and equipment, net	$	133,494	$	131,588

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
INTANGIBLE ASSETS [Abstract]
Schedule of goodwill	We allocated goodwill to our new reporting units using a relative fair value approach.
		March 31,		December 31,
		2015		2014
	Specialty Products	$	7,160	$	7,160
	SensoryEffects		363,784		363,784
	Animal Nutrition and Health		11,734		11,734
	Industrial Products		1,228		1,228
	Total	$	383,906	$	383,906
Intangible assets with finite lives	Identifiable intangible assets with finite lives at March 31, 2015 and December 31, 2014 are summarized as follows:
		Amortization		Gross		Accumulated		Gross		Accumulated
		Period		Carrying		Amortization		Carrying		Amortization
		(in years)		Amount at 3/31/15		at 3/31/15		Amount at		at 12/31/14
								12/31/14
	Customer relationships & lists		10	$	167,442	$	46,822	$	167,442	$	41,238
	Trademarks & trade names		17		32,014		3,332		32,014		2,540
	Developed technology		5		3,200		577		3,200		420
	Regulatory registration costs		10-May		2,012		705		1,704		667
	Patents & trade secrets		15-17		1,705		955		1,665		933
	Other		10-May		754		601		754		587
				$	207,127	$	52,992	$	206,779	$	46,385

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	3 Months Ended
	Mar. 31, 2015
LONG-TERM DEBT [Abstract]
Future minimum debt payments	The following table summarizes the future minimum debt payments:
		2015		2016		2017		2018		2019
	Current portion of long-term debt	$	26,250	$	8,750		-		-		-
	Long-term debt		-		26,250	$	35,000	$	35,000	$	192,500
	Total	$	26,250	$	35,000	$	35,000	$	35,000	$	192,500

NET_EARNINGS_PER_SHARE_Tables

NET EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
NET EARNINGS PER SHARE [Abstract]
Reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:
	Three months ended March 31, 2015	Net		Number of		Per Share
		Earnings		Shares		Amount
		(Numerator)		(Denominator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	15,172		30,842,208	$	0.49
	Effect of dilutive securities – stock options and restricted stock				616,096
	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	15,172		31,458,304	$	0.48
	Three months ended March 31, 2014	Net		Number of		Per Share
		Earnings		Shares		Amount
		(Numerator)		(Denominator)
	Basic EPS – Net earnings and weighted average common shares outstanding	$	8,894		30,146,705	$	0.3
	Effect of dilutive securities – stock options and restricted stock				932,299
	Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	$	8,894		31,079,004	$	0.29

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION [Abstract]
Segment reporting information, by segment	Business Segment Assets:
		March 31,			December 31,
		2015			2014
	Specialty Products	$	25,752		$	24,913
	SensoryEffects		652,470			656,130
	Animal Nutrition & Health		92,804			90,650
	Industrial Products		21,597			32,330
	Other Unallocated		62,219			57,508
	Total	$	854,842		$	861,531
	Depreciation/Amortization:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	341		$	360
	SensoryEffects		7,639			299
	Animal Nutrition & Health		1,546			1,521
	Industrial Products		343			451
	Total	$	9,869		$	2,631
	Capital Expenditures:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	211		$	17
	SensoryEffects		2,626			298
	Animal Nutrition & Health		3,260			704
	Industrial Products		271			119
	Total	$	6,368		$	1,138
	Business Segment Net Sales:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	13,579		$	12,792
	SensoryEffects		67,757			12,150
	Animal Nutrition & Health		42,706			40,853
	Industrial Products		20,820			20,200
	Total	$	144,862		$	85,995
	Business Segment Earnings Before Income Taxes:
		Three Months Ended
		March 31,
		2015			2014
	Specialty Products	$	5,701		$	4,806
	SensoryEffects		7,706			2,601
	Animal Nutrition & Health		8,510			4,159
	Industrial Products		3,121			3,134
	Transaction and integration costs		-			(1,345	)
	Interest and other income (expense)		(1,953	)		17
	Total	$	23,085		$	13,372
Geographic revenue information	The following table summarizes domestic (U.S.) and foreign sales for the three months ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015			2014
	Domestic	$	121,776		$	56,144
	Foreign		23,086			29,851
	Total	$	144,862		$	85,995

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]
Supplemental cash flow information	Cash paid during the three months ended March 31, 2015 and 2014 for income taxes and interest is as follows:
		Three months Ended
		March 31,
			2015		2014
	Income taxes		$	5,527	$	1,640
	Interest		$	1,723	$	-

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	3 Months Ended
	Mar. 31, 2015
ACCUMULATED OTHER COMPREHENSIVE LOSS [Abstract]
Changes in accumulated other comprehensive income (loss)	The changes in accumulated other comprehensive loss were as follows:
		Three Months Ended
		March 31,
		2015			2014
	Net foreign currency translation adjustment	$	(2,680	)	$	(18	)
	Net change in postretirement benefit plan (see Note 13 for further information)
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		-			2
	Total before tax		(5	)		(3	)
	Tax		2			1
	Net of tax		(3	)		(2	)
	Total other comprehensive loss	$	(2,683	)	$	(20	)
	Accumulated other comprehensive loss at March 31, 2015 consisted of the following:
		Foreign currency			Postretirement			Total
		translation			benefit plan
		adjustment
	Balance December 31, 2014	$	(2,702	)	$	51		$	(2,651	)
	Other comprehensive loss		(2,680	)		(3	)		(2,683	)
	Balance March 31, 2015	$	(5,382	)	$	48		$	(5,334	)

EMPLOYEE_BENEFIT_PLAN_Tables

EMPLOYEE BENEFIT PLAN (Tables)	3 Months Ended
	Mar. 31, 2015
EMPLOYEE BENEFIT PLAN [Abstract]
Components of net periodic benefit cost	Net periodic benefit costs for such retirement medical plan were as follows:
		Three months Ended
		March 31,
		2015			2014
	Service cost	$	13		$	14
	Interest cost		9			12
	Amortization of prior service credit		(5	)		(5	)
	Amortization of loss		-			2
	Net periodic benefit cost	$	17		$	23

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
Aggregate future minimum rental payments required under non-cancelable operating leases	Aggregate future minimum rental payments required under all non-cancelable operating leases at March 31, 2015 are as follows:
	Year
	April 1, 2015 to December 31, 2015	$	1,589
	2016		1,818
	2017		1,580
	2018		1,309
	2019		789
	2020		499
	Thereafter		1,937
	Total minimum lease payments	$	9,521

CONDENSED_CONSOLIDATED_FINANCI1

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Goodwill [Member]
Revision of Prior Period Financial Statements [Abstract]
Increase in retrospectively revision from prior periods	$260
Deferred Taxes [Member]
Revision of Prior Period Financial Statements [Abstract]
Increase in retrospectively revision from prior periods	$260

ACQUISITION_OF_PERFORMANCE_CHE2

ACQUISITION OF PERFORMANCE CHEMICALS & INGREDIENTS COMPANY (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	7-May-14	Dec. 31, 2014
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Indemnification asset	$1,976,000
Goodwill	383,906,000			383,906,000
Unaudited pro forma information [Abstract]
SensoryEffects actual results included in the Company's consolidated income statement from January 1, 2015 through March 31, 2015, Net sales	54,540,000	0
SensoryEffects actual results included in the Company's consolidated income statement from January 1, 2015 through March 31, 2015, Net earnings	2,906,000	0
Supplemental pro forma combined financial information, Net Sales	144,862,000	144,607,000
Supplemental pro forma combined financial information, Net Earnings	15,172,000	11,852,000
Basic earnings per share (in dollars per share)	$0.49	$0.39
Diluted earnings per share (in dollars per share)	$0.48	$0.38
Performance Chemicals and Ingredients Company [Member]
Business Acquisition [Line Items]
Percentage owned of the "Acquisition" (in hundredth)			100.00%
Purchase price			569,000,000
Tax deductible for income tax purposes			20,466,000
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Cash and cash equivalents			2,635,000
Accounts receivable			25,674,000
Inventories			32,000,000
Property, plant and equipment			75,850,000
Customer relationships			130,300,000
Trade names			31,100,000
Developed technology			3,200,000
Other assets			3,955,000
Indemnification asset			1,650,000
Trade accounts payable			-10,427,000
Accrued expenses			-6,326,000
Bank debt			-75,550,000
Deferred income taxes			-75,760,000
Goodwill			355,391,000
Amount paid to shareholders			493,692,000
SensoryEffects bank debt paid on purchase date			75,550,000
Total amount paid on acquisition date			569,242,000
Deferred income taxes and goodwill	260,000
Unaudited pro forma information [Abstract]
Acquisition-related costs	1,268,000
Performance Chemicals and Ingredients Company [Member] | Minimum [Member]
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Increase in indemnification asset balance	54,000
Performance Chemicals and Ingredients Company [Member] | Maximum [Member]
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Increase in indemnification asset balance	$1,976,000
Performance Chemicals and Ingredients Company [Member] | Customer Relationships [Member]
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Useful life of intangible assets acquired	10 years
Performance Chemicals and Ingredients Company [Member] | Trade Names [Member]
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Useful life of intangible assets acquired	10 years
Performance Chemicals and Ingredients Company [Member] | Developed Technology [Member]
Estimated fair values of the assets acquired and liabilities assumed [Abstract]
Useful life of intangible assets acquired	5 years

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards (in shares)	3,825,592
Weighted average grant date fair value [Abstract]
Unrecognized compensation cost related to non-vested shares	$10,622	$8,259
Weighted-average period of recognition for unrecognized compensation cost	1 year 9 months 18 days
Estimated share-based compensation expense for current fiscal year	4,700
Stock splits and repurchase of common stock
Number of shares authorized to be repurchased (in shares)	3,763,038
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares)	2,105,231
Number of shares acquired under stock repurchase plan (in shares)	0
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Impact of compensation cost on net earnings	-760	-653
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Impact of compensation cost on earnings component	212	148
Operating Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Impact of compensation cost on earnings component	962	840
Stock Options [Member]
Weighted Average Assumptions [Abstract]
Dividend yield (in hundredths)	0.60%	0.60%
Expected volatility (in hundredths)	33.00%	33.00%
Risk-free interest rate (in hundredths)	1.80%	1.70%
Expected term	5 years 6 months	5 years 7 months 6 days
Vesting period	3 years
Stock Option Activity [Abstract]
Outstanding at beginning of period (in shares)	1,470,000	1,893,000
Granted (in shares)	197,000	158,000
Exercised (in shares)	-192,000	-125,000
Forfeited (in shares)	-1,000	-13,000
Outstanding at end of period (in shares)	1,474,000	1,913,000
Exercisable at end of period (in shares)	1,040,000	1,504,000
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$27.35	$20.94
Granted (in dollars per share)	$58.52	$50.57
Exercised (in dollars per share)	$16.52	$10.60
Forfeited (in dollars per share)	$45.08	$43.10
Outstanding at end of period (in dollars per share)	$32.93	$23.92
Exercisable, end of period (in dollars per share)	$24.75	$19.28
Aggregate Intrinsic Value, Outstanding, beginning of period	57,742	71,465
Aggregate Intrinsic Value, Outstanding, end of period	33,736	53,946
Aggregate Intrinsic Value, Exercisable, end of period	31,849	49,392
Weighted Average Remaining Contractual Term, Outstanding	6 years 2 months 12 days	5 years 7 months 6 days
Weighted Average Remaining Contractual Term, Exercisable	4 years 10 months 24 days	4 years 8 months 12 days
Weighted-average fair value of options granted (in dollars per share)	$18.42	$15.98
Total intrinsic value of stock options exercised	$8,039	$5,418
Restricted Stock [Member]
Non-vested restricted stock [Roll Forward]
Non-vested balance as of beginning of period (in shares)	134,000	172,000
Granted (in shares)	19,000	20,000
Vested (in shares)	-10,000	-2,000
Forfeited (in shares)	0	-2,000
Non-vested balance as of end of period (in shares)	143,000	188,000
Weighted average grant date fair value [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$38.13	$33.69
Granted (in dollars per share)	$58.52	$50.49
Vested (in dollars per share)	$14.37	$35.79
Forfeited (in dollars per share)	$0	$32.70
Non-vested balance as of end of period (in dollars per share)	$42.53	$35.42
Restricted Stock [Member] | Employee [Member]
Weighted Average Assumptions [Abstract]
Vesting period	4 years
Performance Shares [Member] | Employee [Member]
Weighted Average Assumptions [Abstract]
Dividend yield (in hundredths)	0.50%
Expected volatility (in hundredths)	34.00%
Risk-free interest rate (in hundredths)	1.00%
Vesting period	3 years
Non-vested restricted stock [Roll Forward]
Granted (in shares)	24,010
Weighted average grant date fair value [Abstract]
Granted (in dollars per share)	$58.78
Initial TSR (in hundredths)	-6.90%
Cliff vest (in hundredths)	100.00%
Minimum [Member] | Restricted Stock [Member] | Non-employee Director [Member]
Weighted Average Assumptions [Abstract]
Vesting period	4 years
Maximum [Member] | Restricted Stock [Member] | Non-employee Director [Member]
Weighted Average Assumptions [Abstract]
Vesting period	7 years
ISO Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted	10 years
Non-Qualified Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted	10 years

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
INVENTORIES [Abstract]
Raw materials	$17,745	$19,822
Work in progress	2,439	1,989
Finished goods	30,267	27,812
Total inventories	$50,451	$49,623

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$196,974	$195,299
Less: accumulated depreciation	63,480	63,711
Property, plant and equipment, net	133,494	131,588
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,997	3,130
Building [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	30,723	31,030
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	149,035	150,170
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$14,218	$10,969

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill	$383,906	$383,906
Identifiable intangible assets [Abstract]
Gross Carrying Amount	207,127	206,779
Accumulated Amortization	52,992	46,385
Amortization of identifiable finite-lived intangible assets [Abstract]
Amortization of identifiable intangible assets	6,600
Finite-lived intangible assets, future amortization expense [Abstract]
Remainder of 2015	19,900
2016	24,350
2017	20,350
2018	18,100
2019	16,250
2020	14,500
Indefinite-lived intangible assets	0
Customer Relationships & Lists [Member]
Identifiable intangible assets [Abstract]
Amortization period	10 years	10 years
Gross Carrying Amount	167,442	167,442
Accumulated Amortization	46,822	41,238
Trademarks & Trade Names [Member]
Identifiable intangible assets [Abstract]
Amortization period	17 years	17 years
Gross Carrying Amount	32,014	32,014
Accumulated Amortization	3,332	2,540
Developed Technology [Member]
Identifiable intangible assets [Abstract]
Amortization period	5 years	5 years
Gross Carrying Amount	3,200	3,200
Accumulated Amortization	577	420
Regulatory Registration Costs [Member]
Identifiable intangible assets [Abstract]
Gross Carrying Amount	2,012	1,704
Accumulated Amortization	705	667
Regulatory Registration Costs [Member] | Minimum [Member]
Identifiable intangible assets [Abstract]
Amortization period	5 years	5 years
Regulatory Registration Costs [Member] | Maximum [Member]
Identifiable intangible assets [Abstract]
Amortization period	10 years	10 years
Patents & Trade Secrets [Member]
Identifiable intangible assets [Abstract]
Gross Carrying Amount	1,705	1,665
Accumulated Amortization	955	933
Patents & Trade Secrets [Member] | Minimum [Member]
Identifiable intangible assets [Abstract]
Amortization period	15 years	15 years
Patents & Trade Secrets [Member] | Maximum [Member]
Identifiable intangible assets [Abstract]
Amortization period	17 years	17 years
Other [Member]
Identifiable intangible assets [Abstract]
Gross Carrying Amount	754	754
Accumulated Amortization	601	587
Other [Member] | Minimum [Member]
Identifiable intangible assets [Abstract]
Amortization period	5 years	5 years
Other [Member] | Maximum [Member]
Identifiable intangible assets [Abstract]
Amortization period	10 years	10 years
Specialty Products [Member]
Goodwill [Line Items]
Goodwill	7,160	7,160
Sensory Effects [Member]
Goodwill [Line Items]
Goodwill	363,784	363,784
Animal Nutrition and Health [Member]
Goodwill [Line Items]
Goodwill	11,734	11,734
Industrial Products [Member]
Goodwill [Line Items]
Goodwill	$1,228	$1,228

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Debt outstanding	$323,750
Term loan quarterly payment		8,750
Maturity date	7-May-19
Term loan interest rate (in hundredth)	1.67%
Undrawn revolving loan	100,000
Maturities of Long-term Debt [Abstract]
2015	26,250
2016	35,000
2017	35,000
2018	35,000
2019	192,500
Capitalized costs net of accumulated amortization	1,982
Amortization expense pertaining to Capitalized costs	157
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Amount of loan	350,000
Revolving Loan [Member]
Debt Instrument [Line Items]
Amount of loan	100,000
Revolving loan used for funding of acquisition and general corporate purposes	50,000
Current Portion of Long-term Debt [Member]
Maturities of Long-term Debt [Abstract]
2015	26,250
2016	8,750
2017	0
2018	0
2019	0
Long-term Debt [Member]
Maturities of Long-term Debt [Abstract]
2015	0
2016	26,250
2017	35,000
2018	35,000
2019	$192,500

NET_EARNINGS_PER_SHARE_Details

NET EARNINGS PER SHARE (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Earnings (Numerator) [Abstract]
Basic EPS - Net earnings	$15,172	$8,894
Diluted EPS - Net earnings	$15,172	$8,894
Number of Shares (Denominator) [Abstract]
Basic EPS - Weighted average common shares outstanding (in shares)	30,842,208	30,146,705
Effect of dilutive securities - stock options and restricted stock (in shares)	616,096	932,299
Diluted EPS - Weighted average common shares outstanding and effect of stock options and restricted stock (in shares)	31,458,304	31,079,004
Per Share Amount [Abstract]
Basic EPS - Net earnings (in dollars per share)	$0.49	$0.30
Diluted EPS - Net earnings (in dollars per share)	$0.48	$0.29
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)	399,868	11,500

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
INCOME TAXES [Abstract]
Estimated fair value	$1,976
Indemnification asset	1,976
Unrecognized tax benefits	5,400	5,200
Accrued interest and penalties	$1,810	$1,643

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Facility
SEGMENT INFORMATION [Abstract]
Percentage decrease of chlorides released in environment	75.00%
Number of filing facilities	2
Segment information [Abstract]
Assets	$854,842		$861,531
Depreciation and amortization	9,869	2,631
Capital expenditures	6,368	1,138
Net sales	144,862	85,995
Earnings before income taxes	23,085	13,372
Transaction and integration costs	0	-1,345
Interest and other income (expense)	-1,953	17
Specialty Products [Member] | Reportable Segments [Member]
Segment information [Abstract]
Assets	25,752		24,913
Depreciation and amortization	341	360
Capital expenditures	211	17
Net sales	13,579	12,792
Earnings before income taxes	5,701	4,806
SensoryEffects [Member] | Reportable Segments [Member]
Segment information [Abstract]
Assets	652,470		656,130
Depreciation and amortization	7,639	299
Capital expenditures	2,626	298
Net sales	67,757	12,150
Earnings before income taxes	7,706	2,601
Animal Nutrition & Health [Member] | Reportable Segments [Member]
Segment information [Abstract]
Assets	92,804		90,650
Depreciation and amortization	1,546	1,521
Capital expenditures	3,260	704
Net sales	42,706	40,853
Earnings before income taxes	8,510	4,159
Industrial Products [Member] | Reportable Segments [Member]
Segment information [Abstract]
Assets	21,597		32,330
Depreciation and amortization	343	451
Capital expenditures	271	119
Net sales	20,820	20,200
Earnings before income taxes	3,121	3,134
Other Unallocated [Member] | Reportable Segments [Member]
Segment information [Abstract]
Assets	$62,219		$57,508

SEGMENT_INFORMATION_Revenues_F

SEGMENT INFORMATION, Revenues From External Customers and Long-Lived Assets (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$144,862	$85,995
Domestic [Member] | Reportable Geographical Components [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	121,776	56,144
Foreign [Member] | Reportable Geographical Components [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$23,086	$29,851

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash paid during the period [Abstract]
Income taxes	$5,527	$1,640
Interest	$1,723	$0

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Changes in accumulated other comprehensive loss [Abstract]
Net foreign currency translation adjustment	($2,680)	($18)
Net change in postretirement benefit plan (see Note 13 for further information)
Amortization of prior service credit	-5	-5
Amortization of loss	0	2
Total before tax	-5	-3
Tax	2	1
Net of tax	-3	-2
Accumulated Other Comprehensive Loss [Line Items]
Accumulated other comprehensive loss	-2,651
Other comprehensive loss	-2,683	-20
Accumulated other comprehensive loss	-5,334
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Loss [Line Items]
Accumulated other comprehensive loss	-2,702
Other comprehensive loss	-2,680
Accumulated other comprehensive loss	-5,382
Postretirement Benefit Plan [Member]
Accumulated Other Comprehensive Loss [Line Items]
Accumulated other comprehensive loss	51
Other comprehensive loss	-3
Accumulated other comprehensive loss	$48

EMPLOYEE_BENEFIT_PLAN_Details

EMPLOYEE BENEFIT PLAN (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Components of net periodic benefit cost [Abstract]
Service cost	$13	$14
Interest cost	9	12
Amortization of prior service credit	-5	-5
Amortization of loss	0	2
Net periodic benefit cost	17	23
Amount recognized in consolidated balance sheet for benefit obligations (included in other long-term obligations)	$1,134		$1,111
Historical cash payments for retirement medical plan claims per year	less than $100

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005	Dec. 31, 2004
	Seller				sqft
	Area
Operating Leased Assets [Line Items]
Operating lease term					6 years
Office space subject to operating lease					20,000
Rent expense charged to operations	$547	$269
Future minimum rental payments required under all non-cancelable operating leases [Abstract]
April 1, 2015 to December 31, 2015	1,589
2016	1,818
2017	1,580
2018	1,309
2019	789
2020	499
Thereafter	1,937
Total minimum lease payments	9,521
Slate Hill, New York site [Abstract]
Annual monitoring costs, maximum	$5		$5	$5	$5	$5	$5	$5	$5	$5	$5	$5	$5
Verona, Missouri facility [Abstract]
Number of areas of the site in which capping of areas of residual contamination was performed	4
Monitoring period for groundwater and surface water prior to submission of risk assessment report	2 years
Number of sellers who have the benefit of certain contractual indemnification by the prior owner	1
SensoryEffects [Member]
Operating Leased Assets [Line Items]
Operating lease term	6 years 9 months			3 years
Office space subject to operating lease	9,100
Warehouse space subject to operating lease				40,000

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) (Money Market Funds [Member], Level 1 [Member], USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Money Market Funds [Member] | Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$772